Both in Pharmaceuticals
Supernus vs Ultragenyx Pharmaceutical
Over the past year SUPN returned −50.5% and RARE returned −47.1%; their daily moves had a correlation of 0.06.
SUPN −50.5% RARE −47.1%Growth of $1, one year, split-adjusted
| Metric | SUPN | RARE |
|---|---|---|
| Price | $28.21 | $17.16 |
| Market cap | $1.64B | $1.69B |
| Today | +0.21% | +3.19% |
| 1 month | −34.1% | +18.7% |
| 6 months | −45.2% | −33.8% |
| Year to date | −43.2% | −25.4% |
| 1 year | — | −48.7% |
| Revenue growth (YoY) | +18.0% | +28.1% |
| Gross margin | 88.1% | 84.1% |
| Net margin | 9.2% | −43.0% |
| P/E (TTM) | — | — |
| Price / sales | 1.9× | 2.4× |
| Net cash | $359.5M | $292.0M |
| Dividend yield | 28.82% | — |
| Volatility (60d) | 86.1% | 128.5% |
| Short % of float | 7.3% | 21.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).